Table 2.
Analysis of individual components of the OAB-S Medication Tolerability score at end of treatment in the full analysis set
| Side effect | Treatment | Total number of patientsa | Did not have side effects, n (%) | Had side effects, n (%) | ||||
|---|---|---|---|---|---|---|---|---|
| Bothered a lot | Bothered moderately | Bothered somewhat | Bothered little | Did not bother | ||||
| Constipation | Mirabegron | 335 | 233 (69.6) | 11 (3.3) | 12 (3.6) | 20 (6.0) | 40 (11.9) | 19 (5.7) |
| Tolterodine | 330 | 227 (68.8) | 10 (3.0) | 11 (3.3) | 28 (8.5) | 37 (11.2) | 17 (5.2) | |
| Dry mouth | Mirabegron | 336 | 190 (56.5) | 18 (5.4) | 21 (6.3) | 27 (8.0) | 59 (17.6) | 21 (6.3) |
| Tolterodine | 330 | 147 (44.5) | 46 (13.9) | 28 (8.5) | 23 (7.0) | 65 (19.7) | 21 (6.4) | |
| Drowsiness | Mirabegron | 336 | 200 (59.5) | 12 (3.6) | 21 (6.3) | 32 (9.5) | 46 (13.7) | 25 (7.4) |
| Tolterodine | 330 | 201 (60.9) | 21 (6.4) | 18 (5.5) | 25 (7.6) | 40 (12.1) | 25 (7.6) | |
| Headache | Mirabegron | 335 | 228 (68.1) | 12 (3.6) | 11 (3.3) | 21 (6.3) | 42 (12.5) | 21 (6.3) |
| Tolterodine | 330 | 221 (67.0) | 10 (3.0) | 16 (4.8) | 18 (5.5) | 42 (12.7) | 23 (7.0) | |
| Nausea | Mirabegron | 335 | 262 (78.2) | 3 (0.9) | 9 (2.7) | 8 (2.4) | 26 (7.8) | 27 (8.1) |
| Tolterodine | 330 | 252 (76.4) | 6 (1.8) | 9 (2.7) | 8 (2.4) | 20 (6.1) | 35 (10.6) | |
| Blurred vision | Mirabegron | 335 | 238 (71.0) | 10 (3.0) | 14 (4.2) | 10 (3.0) | 42 (12.5) | 21 (6.3) |
| Tolterodine | 330 | 233 (70.6) | 4 (1.2) | 12 (3.6) | 16 (4.8) | 38 (11.5) | 27 (8.2) | |
aTotal number of patients at each visit per sequence and treatment